Close Menu

Quickly and cheaply is the goal of Pathogenica, a start-up that proposes to diagnose diseases using sequencing technology, reports MIT's Technology Review. By the end of 2012, the company hopes to have an FDA-approved product to detect the bacteria behind urinary tract infections, all for $10 a test. "The majority [of current tests] require days to get a result, which is frequently too late," says Columbia University's Ian Lipkin, who is on Pathogenica's board, to Tech Review.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.